ADMA Biologics (NASDAQ:ADMA) Upgraded at Zacks Research

Zacks Research upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a hold rating to a strong-buy rating in a research report released on Monday,Zacks.com reports.

Several other analysts have also recently issued reports on the company. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $32.00.

ADMA Biologics Stock Up 1.0%

Shares of ADMA Biologics stock opened at $16.54 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The stock has a market cap of $3.94 billion, a price-to-earnings ratio of 27.57 and a beta of 0.51. The firm’s 50-day moving average is $17.07 and its two-hundred day moving average is $16.80. ADMA Biologics has a 1 year low of $13.76 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the prior year, the company earned $0.46 EPS. The company’s revenue was up 18.4% compared to the same quarter last year. As a group, research analysts expect that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp boosted its holdings in ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after acquiring an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP raised its position in shares of ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after purchasing an additional 2,415,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after purchasing an additional 1,886,105 shares in the last quarter. Capital Research Global Investors boosted its stake in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after purchasing an additional 3,383,559 shares in the last quarter. Finally, Nuveen LLC grew its position in ADMA Biologics by 3.5% during the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock worth $108,097,000 after purchasing an additional 202,245 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.